NVO novonordisk.com: Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan

Novo Nordisk AS - logo grafis emiten NVO

Novo Nordisk A/S (NVO) dominance in the weight loss and diabetes segment creates a powerful defensive barrier for profits. The EV/EBITDA value, accounting for total debt, has stabilized at 5.52 on the base chart of the GURU.Markets service, confirming the resilience of the valuation. Growth is driven by breakthrough GLP-1 developments in peptide engineering and a zero-environmental-footprint strategy for the recycling of medical devices.

Novo Nordisk AS - Nilai perusahaan marang bathi operasional sadurunge panyusutan NVO (periode 23.11.2025 - 17.11.2026)

Novo Nordisk - rincian analitis lan metrik utama (NVO)

- data kapitalisasi saham perusahaan:
Analisis dhasar perusahaan:NVO (Novo Nordisk)
Produk asli novonordisk.com

Investors use this ratio to determine the fair value of a company relative to its ability to generate cash flow. The metric compares the total enterprise value, including net debt, with operating profit before taxes, depreciation, and amortization. By analyzing the historical EV/EBITDA multiple of a business, one can identify points of asset undervaluation. For Novo Nordisk A/S (NVO), this metric reflects the efficiency of integrating new drug delivery platforms acquired through strategic M&A transactions.